Coronary artery disease and human immunodeficiency virus infection

Clinical Infectious Diseases

Volumn 31, Issue 3, 2000, Pages 787-797

  Passalaris, John D ^a   Sepkowitz, Kent A ^b   Glesby, Marshall J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; ENDOTHELIUM LESION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER TOXICITY; MUSCLE INJURY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; CORONARY DISEASE; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 0034457195     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313995     Document Type: Article

References (107)

1. Heart involvement in AIDS: A prospective study during various stages of disease
2. Cardiac involvement in the acquired immunodeficiency syndrome - A review to push action
3. Cardiac manifestations of AIDS: A review of disease spectrum and clinical management
4. Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinical-pathological study
5. AIDS giving rise to cardiac problems
6. Arteriopathy in children with AIDS
7. Coronary artery lesions and human immunodeficiency virus infection
8. The progression of coronary artery disease and the acute coronary syndromes
9. The progression of coronary artery disease and the acute coronary syndromes
10. A reliable marker of endothelial call dysfunction: Does it exist?
11. The platelet and endothelium in HIV infection
12. Endothelial cell dysfunction in HIV infection
13. Aortic endothelium in HIV-1 infection
14. Plasma hypercoagulability is correlated to plasma HIV load
15. Chlamydia pneumoniae and atherosclerosis
16. Chlamydia pneumoniae antimicrobial therapy and coronary heart disease: A critical overview
17. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?
18. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 β plus tumor necrosis factor-α
19. Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1
20. Hypertriglyceridemia in the acquired immunodeficiency syndrome
21. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex
22. Helsinki Heart Study. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
23. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) Registry
24. The emergence of triglycerides as a significant independent risk in coronary artery
25. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
26. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less
27. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
28. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
29. Marked hypertriglyceridemia associated with ritonavir therapy
30. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors
31. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
32. FDA warns of potential protease-inhibitor link to hyperglycaemia
33. Impaired glucose tolerance and beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
34. Impaired glucose tolerance and protease inhibitors
35. Severe diabetes associated with protease inhibitor therapy
36. Protease inhibitor associated hyperglycemia
37. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors
38. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy
39. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus infected women
40. Hyperlipidemia under treatment with protease inhibitors
41. Marked hyperlipidemia on ritonavir therapy
42. Hyperlipidemia following treatment with protease inhibitors with HIV-1 infection
43. High density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
44. Atherogenic dyslipidemias in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study
45. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middleaged men
46. Pathogenesis of HIV-1 protease-inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
47. Investigations into the proposed mechanisms of HIV-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance
48. Protease inhibitors and adipocyte differentiation in cell culture
49. Effect of HIV protease inhibitors on in vitro adipogenesis and in vivo fat deposition
50. Epidemiological and clinical aspects of the metabolic complications of HIV infection: The fat redistribution syndrome
51. Abnormal fat distribution and use of protease inhibitors
52. Abnormal fat accumulation in patients with HIV-1 infection
53. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy
54. Lipodystrophy in patients naive to HIV protease inhibitors
55. Risk factors for developing lipodystrophy in patients receiving protease inhibitors
56. Clinical factors related to the severity of fat redistribution in the HIV outpatient study (HOPS)
57. Diagnosis, prediction and natural course of lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study
58. Changes in body habitus in HIV positive women after initiation of protease inhibitor therapy
59. Studies of body composition and fat distribution in HIV-infected and control subjects
60. Editorial response: What price progress? Pseudo-Cushing's syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection
61. Metabolic abnormalities and use of HIV-1 protease inhibitors
62. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
63. Abdominal obesity and the development of non-insulin-dependent diabetes mellitus
64. Pathophysiology and pathogenesis of visceral fat obesity
65. The cardiovascular risk associated with impaired glucose tolerance
66. Severe premature coronary artery disease with protease inhibitors
67. Vascular complications associated with the use of HIV protease inhibitors
68. Severe coronary artery disease in a young HIV infected man with no cardiovascular risk factors who was treated with indinavir
69. Myocardial infarction in HIV infected men receiving protease inhibitors
70. Vascular complications associated with the use of HIV protease inhibitors
71. Vascular complications associated with the use of HIV protease inhibitors
72. Myocardial infarction incidence in clinical trials of four protease inhibitors
73. Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients? Additional follow-up
74. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?
75. Endothelial dysfunction is associated with the use of human immunodeficiency virus type 1 protease inhibitors
76. Noninvasive morphological analysis of carotid and femoral arteries in protease-inhibitor-treated HIV-infected individuals
77. Cardiac disease risk factors in a veteran HIV+ population compared to the general USA population
78. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
79. Lack of clinical lipodystrophy in patients receiving efavirenz +NTRIs in study 001
80. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis
81. Summary of the Second Report of the National Cholesterol Education program (NCEP)
82. Atorvastatin and gemfiboizil for protease inhibitor related lipid abnormalities
83. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
84. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
85. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
86. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
87. Hypercholesterolemia during protease inhibitor treatment: Effect of atorvastatin
88. Drug treatment of lipid disorders
89. Highlights of the 71st scientific sessions of the American Heart Association
90. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 positive patients
91. Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz
92. Identification of fat redistribution/metabolic abnormalities in a cohort treated by 2 NRTIs + 1 PI and absence of significant modification following PI substitution
93. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz [abstract 49]
94. Partial improvement in lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz
95. Impact of switching from HIV-1 protease inhibitors to efavirenz in patients with lipodystrophy
96. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
97. A prospective open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months [abstract 45]
98. Clinical, virological, and immunological benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy: 36-Week follow-up
99. A randomized multicenter study of protease inhibitor substitution in aviremic patients with antiretroviral lipodystrophy syndrome
100. Risks and benefits of replacing protease inhibitors with nevirapine in patients with long term successful triple combinations
101. A novel use of abacavir to simplify therapy in PI-experienced patients successfully treated with HAART: CNA30017
102. Swiss HIV Cohort Study. Protease inhibitor class sparing maintenance therapy with abacavir plus lamivudine and zidovudine in patients with long term suppression of HIV-1 RNA
103. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy
104. Amprenavir/3TC/ZDV exerts durable antiviral activity in HIV-1 infected antiretroviral therapy-naive subjects through 48 weeks of therapy
105. Continued viral suppression and decrease of triglycerides and GGT after switch from a ritonavir containing regiment to a nelfinavir or saquinavir/nelfinavir containing regimen